Ace of BACE

Pharma companies have been working on beta secretase as a target for Alzheimer's disease for several years, but problems getting inhibitors across the blood-brain barrier have so far prevented them from getting into the clinic.

Astellas Pharma Inc. has in-licensed rights to the only compound that has overcome that obstacle and made it into human testing, CTS-21166, a beta secretase (BACE1) inhibitor from CoMentis Inc. that has completed a Phase I trial to treat AD.

According to CoMentis, BACE1

Read the full 774 word article

How to gain access

Continue reading with a
two-week free trial.